Molecular Formula | C34H34Cl2F3NO3 |
Molar Mass | 632.55 |
Solubility | DMSO : 150 mg/mL (237.14 mM; ultrasonic and warming and heat to 60°C) |
Storage Condition | -20°C |
In vitro study | RGX-104, an orally administered LXR agonist, potently induces ApoE expression, resulting in endogenous immune-mediated antitumor activity. RGX-104 drives anti-tumor immune responses by modulating the abundance and activity of myeloid-derived suppressor cells and dendritic cells. |
In vivo study | In several syngenic xenograft tumor models, RGX-104 monotherapy elicits a tumor response, including melanoma, ovarian cancer, lung cancer, and glioblastoma multiforme. This antitumor activity via activation of LXR is associated with constitutive upregulation of ApoE expression. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 1.581 ml | 7.905 ml | 15.809 ml |
5 mM | 0.316 ml | 1.581 ml | 3.162 ml |
10 mM | 0.158 ml | 0.79 ml | 1.581 ml |
5 mM | 0.032 ml | 0.158 ml | 0.316 ml |
biological activity | RGX-104 is an orally active liver X receptor agonist, endogenous immune responses can be regulated by transcriptional activation of the ApoE gene. |
Target | Value |